Strongbridge Announces RECORLEV™ (levoketoconazole)

 

Strongbridge RGBStrongbridge Biopharma plc announced positive top-line results from the pivotal Phase 3 LOGICS study of RECORLEV™ (levoketoconazole) for the treatment of endogenous Cushing’s syndrome, which met its primary endpoint with high statistical significance.

 

Please see the press release here:

 

Print